BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 3116031)

  • 21. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced disparity of gonadotropin secretion by estrone in women with polycystic ovarian disease.
    Chang RJ; Mandel FP; Lu JK; Judd HL
    J Clin Endocrinol Metab; 1982 Mar; 54(3):490-4. PubMed ID: 6799536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
    Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis.
    Meldrum DR; Chang RJ; Lu J; Vale W; Rivier J; Judd HL
    J Clin Endocrinol Metab; 1982 May; 54(5):1081-3. PubMed ID: 6801075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pituitary-ovarian response to the gonadotrophin-releasing hormone-agonist test in anovulatory patients with polycystic ovary syndrome: predictive role of ovarian stroma.
    Fulghesu AM; Angioni S; Belosi C; Apa R; Selvaggi L; Ciampelli M; Iuculano A; Melis GB; Lanzone A
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):396-401. PubMed ID: 16918963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ovarian suppression in polycystic ovarian disease during 6 month administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.
    Faure N; Lemay A
    Clin Endocrinol (Oxf); 1987 Dec; 27(6):703-13. PubMed ID: 3138052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours.
    Pascale MM; Pugeat M; Roberts M; Rousset H; Déchaud H; Dutrieux-Berger N; Tourniaire J
    Clin Endocrinol (Oxf); 1994 Nov; 41(5):571-6. PubMed ID: 7828344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin).
    Andreyko JL; Monroe SE; Jaffe RB
    J Clin Endocrinol Metab; 1986 Oct; 63(4):854-9. PubMed ID: 2943756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pituitary responsiveness to gonadotrophin-releasing hormone agonist stimulation: a dose-response comparison of luteinizing hormone/follicle-stimulating hormone secretion in women with polycystic ovary syndrome and normal women.
    Cheung AP; Chang RJ
    Hum Reprod; 1995 May; 10(5):1054-9. PubMed ID: 7657740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
    Graña-Barcia M; Liz-Lestón J; Lado-Abeal J
    Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound.
    Carmina E; Wong L; Chang L; Paulson RJ; Sauer MV; Stanczyk FZ; Lobo RA
    Hum Reprod; 1997 May; 12(5):905-9. PubMed ID: 9194637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of gonadotrophin-releasing hormone analogue (GnRH-A) administration on serum gonadotrophin and steroid levels in patients with polycystic ovarian disease.
    Mongioi A; Maugeri G; Macchi M; Calogero A; Vicari E; Coniglione F; Aliffi A; Sipione C; D'Agata R
    Acta Endocrinol (Copenh); 1986 Feb; 111(2):228-34. PubMed ID: 3082098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome.
    Barnes RB; Rosenfield RL; Burstein S; Ehrmann DA
    N Engl J Med; 1989 Mar; 320(9):559-65. PubMed ID: 2521688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Titrating luteinizing hormone surge requirements for ovulatory changes in primate follicles. I. Oocyte maturation and corpus luteum function.
    Zelinski-Wooten MB; Lanzendorf SE; Wolf DP; Chandrasekher YA; Stouffer RL
    J Clin Endocrinol Metab; 1991 Sep; 73(3):577-83. PubMed ID: 1908481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
    Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
    J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist.
    Steingold KA; Cedars M; Lu JK; Randle D; Judd HL; Meldrum DR
    Obstet Gynecol; 1987 Mar; 69(3 Pt 1):403-11. PubMed ID: 2950349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
    Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
    Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of endometriosis in monkeys: effectiveness of continuous infusion of a gonadotropin-releasing hormone agonist compared to treatment with a progestational steroid.
    Mann DR; Collins DC; Smith MM; Kessler MJ; Gould KG
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1277-83. PubMed ID: 3097054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polycystic ovaries in nonobese adolescents and young women with ovarian androgen excess: relation to prenatal growth.
    Ibáñez L; López-Bermejo A; Callejo J; Torres A; Cabré S; Dunger D; de Zegher F
    J Clin Endocrinol Metab; 2008 Jan; 93(1):196-9. PubMed ID: 17956949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pituitary and ovarian responses to LHRH stimulation in women with clinical features of the polycystic ovary syndrome.
    Heineman MJ; Thomas CM; Doesburg WH; Rolland R
    Eur J Obstet Gynecol Reprod Biol; 1984 Jun; 17(4):273-84. PubMed ID: 6430731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.